Melatonin treatment in children with therapy-resistant monosymptomatic nocturnal enuresis.
Study Goal
The researchers aimed to evaluate the effects of exogenous melatonin on wet night frequency, sleep-wake cycle, and melatonin profiles in children with therapy-resistant MNE.
Results Summary
The study found that exogenous melatonin altered melatonin profiles but did not affect enuresis frequency or sleep-wake cycles in the studied patients. No significant differences were observed between the melatonin and placebo groups.
Population
Children with therapy-resistant monosymptomatic nocturnal enuresis (MNE).
Effective Dosage
Not specified
Duration
6 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
exogenous melatonin | change | melatonin profile | children with therapy-resistant MNE | - | observed a change in profile | #1 |
exogenous melatonin | no change | sleep-wake cycle | children with therapy-resistant MNE | - | did not observe a difference | #2 |
exogenous melatonin | no change | frequency of wet nights | children with therapy-resistant MNE | - | did not observe a difference | #3 |
exogenous melatonin | no change | enuresis frequency | this select group of patients | - | did not observe a change | #4 |
exogenous melatonin | no change | sleep-wake cycle | this select group of patients | - | did not observe a change | #5 |
OBJECTIVE: To evaluate the effects of exogenous melatonin on the frequency of wet nights, on the sleep-wake cycle, and on the melatonin profile in children with therapy-resistant MNE. PATIENTS AND METHODS: 24 patients were included. Patients had to maintain a diary including time of sleep and arousal, and whether they had a dry or a wet bed in the morning. We measured baseline melatonin profiles in saliva. Hereafter, patients were randomized to synthetic melatonin or placebo. After 3 and 6 months we evaluated the frequency of enuresis and the melatonin profiles. RESULTS: 11 patients were randomized to melatonin, 13 to placebo. We evaluated melatonin profiles of 7 patients in the melatonin group and of 8 in the placebo group. We observed a change in profile in the melatonin group, but we did not observe a difference in the sleep-wake cycle or the frequency of wet nights in either group. CONCLUSION: This is the first time exogenous melatonin has been evaluated in the treatment of MNE. Although we observed a change in melatonin profile after the use of exogenous melatonin, we did not observe a change in enuresis frequency or in the sleep-wake cycle of this select group of patients.